Evidence map›Paper›PMID 37390077›Full record

ArticlePLOS digital health2023

Implementation, feasibility, and acceptability of 99DOTS-based supervision of treatment for drug-susceptible TB in Uganda.

Noah Kiwanuka, Alex Kityamuwesi, Rebecca Crowder, Kevin Guzman, Christopher A Berger, Maureen Lamunu, Catherine Namale, Lynn Kunihira Tinka, Agnes Sanyu Nakate, Joseph Ggita and 9 more

Abstract read
In one paragraph

Article in PLOS digital health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Noah KiwanukaDepartment of Epidemiology & Biostatistics, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda.
Alex KityamuwesiWalimu, Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
Rebecca CrowderCenter for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Kevin GuzmanDepartment of Medicine, University of California San Francisco, San Francisco, California, United States.
Christopher A BergerCenter for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.ORCID https://orcid.org/0000-0002-0034-7544
Maureen LamunuWalimu, Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
Catherine NamaleWalimu, Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
Lynn Kunihira TinkaWalimu, Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
Agnes Sanyu NakateWalimu, Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
Joseph GgitaWalimu, Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
Patricia TurimumahoroWalimu, Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
Diana BabiryeWalimu, Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
Denis OyukuWalimu, Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
Devika PatelDepartment of Surgery, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Amanda SammannDepartment of Surgery, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Stavia TuryahabweUganda National Tuberculosis and Leprosy Programme, Ministry of Health, Kampala, Uganda.
David W DowdyDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Achilles KatambaWalimu, Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.ORCID https://orcid.org/0000-0002-2347-4183
Adithya CattamanchiWalimu, Uganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.ORCID https://orcid.org/0000-0002-6553-2601

Funding

Research Mentoring and Building Capacity of underrepresented Minority Research Scientists in India.D43TW010540 · FIC · YALE UNIVERSITY · PI MICHELE BARRY, Eva Harris · 2017 to 2026
$15.5M
FIC NIH HHS D43 TW010540
6 · The paper itself

Abstract

99DOTS is a low-cost digital adherence technology that allows people with tuberculosis (TB) to self-report treatment adherence. There are limited data on its implementation, feasibility, and acceptability from sub-Saharan Africa. We conducted a longitudinal analysis and cross-sectional surveys nested within a stepped-wedge randomized trial at 18 health facilities in Uganda between December 2018 and January 2020. The longitudinal analysis assessed implementation of key components of a 99DOTS-based intervention, including self-reporting of TB medication adherence via toll-free phone calls, automated text message reminders and support actions by health workers monitoring adherence data. Cross-sectional surveys administered to a subset of people with TB and health workers assessed 99DOTS feasibility and acceptability. Composite scores for capability, opportunity, and motivation to use 99DOTS were estimated as mean Likert scale responses. Among 462 people with pulmonary TB enrolled on 99DOTS, median adherence was 58.4% (inter-quartile range [IQR] 38.7-75.6) as confirmed by self-reporting dosing via phone calls and 99.4% (IQR 96.4-100) when also including doses confirmed by health workers. Phone call-confirmed adherence declined over the treatment period and was lower among people with HIV (median 50.6% vs. 63.7%, p<0.001). People with TB received SMS dosing reminders on 90.5% of treatment days. Health worker support actions were documented for 261/409 (63.8%) people with TB who missed >3 consecutive doses. Surveys were completed by 83 people with TB and 22 health workers. Composite scores for capability, opportunity, and motivation were high; among people with TB, composite scores did not differ by gender or HIV status. Barriers to using 99DOTS included technical issues (phone access, charging, and network connection) and concerns regarding disclosure. 99DOTS was feasible to implement and highly acceptable to people with TB and their health workers. National TB Programs should offer 99DOTS as an option for TB treatment supervision.

Identifiers

PMID37390077
PMCPMC10313004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.